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Objectives The aim of this study was to discern the role of the cardiac voltage-gated sodium ion channel SCN5A in the etiol-
ogy of dilated cardiomyopathy (DCM).
Background Dilated cardiomyopathy associates with mutations in the SCN5A gene, but the frequency, phenotype, and caus-
ative nature of these associations remain the focus of ongoing investigation.
Methods Since 1991, DCM probands and family members have been enrolled in the Familial Cardiomyopathy Registry
and extensively evaluated by clinical phenotype. Genomic deoxyribonucleic acid samples from 338 individuals
among 289 DCM families were obtained and screened for SCN5A mutations by denaturing high-performance
liquid chromatography and sequence analysis.
Results We identified 5 missense SCN5A mutations among our DCM families, including novel mutations E446K,
F1520L, and V1279I, as well as previously reported mutations D1275N and R222Q. Of 15 SCN5A mutation
carriers in our study, 14 (93%) manifested arrhythmia: supraventricular arrhythmia (13 of 15), including sick
sinus syndrome (5 of 15) and atrial fibrillation (9 of 15), ventricular tachycardia (5 of 15), and conduction
disease (9 of 15).
Conclusions Mutations in SCN5A were detected in 1.7% of DCM families. Two-thirds (6 of 9) of all reported DCM mutations in
SCN5A localize to the highly conserved homologous S3 and S4 transmembrane segments, suggesting a shared
mechanism of disruption of the voltage-sensing mechanism of this channel leading to DCM. Not surprisingly,
SCN5A mutation carriers show a strong arrhythmic pattern that has clinical and diagnostic implications.
(J Am Coll Cardiol 2011;57:2160–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.084DMost genes associated with dilated cardiomyopathy (DCM)
encode for structural proteins involved with contractile
function and the cytoskeletal matrix (1). Mutations in these
genes are believed to diminish overall structural integrity of
myocytes leading to contractile filament disarray, cell death,
and the development of fibrosis that is characteristic of
dilation (2). Defects identified in calcium and potassium
regulation argue for an alternative disease mechanism of
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electrical excitability rather than a structural defect (3–6).
Our discovery of a D1275N alteration in the ion channel
gene SCN5A associated with DCM suggested that dysfunc-
tion in electrical excitability, caused by disruption of sodium
channel function, also leads to dilation remodeling (7).
See page 2169
Olson et al. (8,9) further substantiated sodium channel
involvement in dilation etiology with independent confir-
mation of the D1275N mutation in another branch of the
same DCM family and through the identification of 3
additional SCN5A missense mutations (T220I, R814W,
1595H) and 1 frameshift mutation (2550-2551 ins TG)
hat associated with DCM. Hershberger et al. (10) recently
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May 24, 2011:2160–8 SCN5A Mutations in Dilated Cardiomyopathyreported 2 additional mutations associated with the dilation
phenotype: I1835T and R222Q.
With established evidence for mutations in SCN5A as a
cause of DCM, we sought to determine the prevalence of
SCN5A mutations in subjects from a large multicenter DCM
cohort, the Familial Cardiomyopathy Registry. Results de-
scribed herein identify additional disease-causing mutations
that we hypothesize act primarily through related mechanisms
of altered electrical excitability leading to pathological ion
dysregulation. Significantly, mutations currently identified as-
sociating with DCM in SCN5A tend to target domains
important for voltage-dependent activation. We conclude that
mutations in voltage-sensitive regions of SCN5A (also known
s Nav 1.5) lead to the eventual manifestation of DCM.
ethods
atient cohort. In all, 338 DCM subjects (including 289
robands) within the Familial Cardiomyopathy Registry
ere screened for SCN5A mutations. Informed consent was
btained from registrants under the institutional review
oard policies of participating institutions. Diagnosis for the
ffected status of DCM was made according to published
riteria (11). Affected subjects and related family members
ere evaluated by investigators. Evaluations included a
omplete medical and family history, physical examination,
2-lead electrocardiogram, and echocardiography. Addi-
ional family members were interviewed, and their medical
istories and medical records were reviewed to allow an
ccurate analysis of the phenotype. For deceased relatives,
ospital records were examined when available, family
hysicians were interviewed, and multiple informants
mong close relatives were consulted for accuracy of
iagnosis.
CN5A mutation screening. Genomic deoxyribonucleic
cid (DNA) was extracted through either peripheral blood
eukocytes or buccal swab sampling (epitope) according to
tandard protocols. The SCN5A coding exons 2 through 28
nd related intronic boundaries were studied. Primers were
esigned utilizing publicly available genetic maps (12) and
ptimized with Primer 3 Input software (13). The DNA
as amplified by polymerase chain reaction.
Genetic screening was accomplished through the use of
enaturing high-performance liquid chromatography on a
AVE Fragment Analysis System (Transgenomic, Omaha,
ebraska). An ABI 377 DNA sequencer (Applied Biosys-
ems, Foster City, California) was utilized for selective
idirectional DNA sequencing of variants manifesting ab-
ormal elution profile on the WAVE system. Sequencing
esults were compared to published sequences in the Na-
ional Center for Biotechnology Information (NCBI) using
asic local alignment search tool (BLAST) algorithms (14).
riteria for the classification of a mutation as putatively
isease causing included the following: predicted alteration
f amino acid sequence, evolutionary conservation of the
articular residue altered, probable effects on protein bio-hysics based on functional studies
f conserved homologous regions
ithin the voltage-gated ion chan-
el family, segregation among af-
ected family members, and ab-
ence in normal controls. For
ontrol data, we used the NCBI
ariation database (dbSNP) (15),
ata from reported literature
nd/or 300 ethnically matched
ontrol chromosomes. Specifi-
ally, for mutations V1279I and
1275N, we studied 300 ethni-
ally-matched control chromo-
omes available in our laboratory. For mutation E446K, we
sed published data of 300 ethnically matched control
hromosomes reported for the same exon (exon 10) (16).
or mutation F1529L (exon 27), we used 500 ethnically
atched controls previously published for the same exon
8). Finally, for R222Q, we used control data in an
thnically matched population for the same mutation as
ublished by Hershberger et al. (10).
esults
issense mutations. The SCN5A mutation screening of
ur DCM population identified 5 missense mutations:
1275N, F1520L, V1279I, E446K, and R222Q. We
eported identifying mutation D1275N previously (7).
Here, we report finding our 4 additional mutations in
subjects among a cohort of 289 DCM families (Figs. 1 and 2).
Of these 4 additional mutations, 3 proved to be novel
(E446K, F1520L, V1279I), and 1 (R222Q) has recently
been identified within a separate DCM pedigree by other
investigators (10). In our population, mutations D1275N,
F1520L, V1279I, and R222Q occurred in conjunction with
familial DCM whereas E446K occurred in an apparently
sporadic form. Phenotype characteristics of SCN5A muta-
tion carriers are detailed in Table 1. The SCN5A mutation
carriers included subjects with overt DCM as well as their
relatives with predominant arrhythmic phenotypes, in par-
ticular in the younger generations. Remarkably, 14 of 15
SCN5A mutations carriers (93%) manifested arrhythmia
such as supraventricular arrhythmia (13 of 15), including
sinus node dysfunction (5 of 15), atrial fibrillation (9 of 15),
ventricular tachycardia (5 of 15), and conduction disease (9
of 15) (Fig. 3). Sinus node dysfunction (or sick sinus
syndrome) in these patients included a range of electro-
physiologic abnormalities, from sinus bradycardia and atrial
standstill to atrial tachyarrhythmias (supraventricular tachy-
cardia, atrial flutter, and atrial fibrillation) (17).
In 3 families (R222Q, F1520L, D1275N), a series of
DCM genes had previously been excluded by screening
analysis in our laboratory, including MYH7, MYH6,
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
DNA  deoxyribonucleic
acid
NYHA  New York Heart
Association
SCN5A  cardiac voltage-
gated sodium ion channel,
alpha subunit
SNP  single nucleotide
polymorphismMYBPC3, ZASP, TNNT2, BAF, and EMD. Two families
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SCN5A Mutations in Dilated Cardiomyopathy May 24, 2011:2160–8(E446K and V1279I) were recently enrolled and not previ-
ously screened for other DCM genes.
Mutation R222Q. Two siblings carried the R222Q varia-
tion (c.665.G¡A), and both shared the same phenotype,
characterized by an early age of significant arrhythmic onset
(19 and 25 years) with symptoms and signs including atrial
fibrillation (II-1 and II-2 of R222Q pedigree) (Fig. 1 and
Table 1). Neither demonstrated symptoms of heart failure
(New York Heart Association [NYHA] functional class I).
In a follow-up of 15 years, they remained stable with no
or minimal additional symptoms. One of the siblings (II-2)
received an implantable cardioverter-defibrillator on the
basis of the severity of his ventricular arrhythmia. The
mother was clinically investigated and found to be
unaffected.
This R222Q variant alters a highly conserved, function-
ally critical, positively charged residue to an uncharged
residue in domain I of the voltage-sensing transmembrane
segment S4 (Fig. 2, Online Table 1) (18–20). Currently,
there are 5 missense changes reported in this S4 transmem-
brane segment, and all associate with disease, including the
Figure 1 Pedigrees in the Familial Cardiomyopathy Registry Co
Missense mutations are listed as pedigree identifiers above related family trees. G
nated by a black arrow. The legend for pertinent clinical information is described
cardioverter-defibrillator.T220I correlation to DCM identified by Olson et al. (8). iThe S4, R222 position is conserved across all domains of
the family of voltage-gated ion channels regardless of
species, including single-domain potassium channels and
distantly related single-domain transient receptor protein
channels (Online Table 1).
Mutation F1520L. The proband of the F1520L (c.4560.C¡G)
edigree demonstrated an early age of onset (26 years) with
bsence of heart failure symptoms at presentation (NYHA
unctional class I) (Fig. 1, Table 1). His abnormal electro-
ardiogram was discovered in a routine screening for com-
etitive basketball players. The family history was charac-
erized by a progressive worsening of phenotype leading
ltimately to heart failure and heart transplantation for the
roband and an affected family member (Fig. 1) despite
ptimal medical therapy performed in heart failure referral
enters.
The novel variant F1520L changes the residue at this
osition from an aromatic ring to an aliphatic side chain. This
hange occurs in the domain III to domain IV (DIII-DIV)
ytosolic linker very near the S1 transmembrane segment of
IV (Fig. 2) (18). This linker region encodes the fast-
ing SCN5A Mutations
tions are denoted by Roman numerals. Probands for each pedigree are desig-
the pedigrees. DCM  dilated cardiomyopathy; ICD  implantablentain
enera
belownactivation gate, and missense mutations R1512W and
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May 24, 2011:2160–8 SCN5A Mutations in Dilated CardiomyopathyK1527R are associated with Brugada syndrome and in close
proximity to position F1520 (21,22). The F1520 residue is
conserved across species within SCN5A but not among homol-
ogous voltage-gated sodium and calcium channel family members
(Online Table 2).
Mutation E446K. The index patient of the E446K
(c.1336.G¡A) pedigree had no clear family history and was
considered a “sporadic” case (Fig. 1, Table 1). He demon-
strated an early age of onset (24 years) and minimal
symptoms of heart failure (NYHA functional class II). He
presented with a history of palpitations, but no evidence of
arrhythmia was found in routine electrocardiograms, and
subsequently, no Holter monitoring was performed. His left
ventricular ejection fraction dramatically improved from
24% to 40% over the 3 years of follow-up. His mother was
clinically unaffected and did not carry the variant allele.
Novel variant E446K is found in the domain I to domain II
(DI-DII) cytosolic linker at the exon-intron splicing boundary
between exons 10 and 11 and alters the charge at this position
from a negatively charged side chain to a positively charged one
(Fig. 2) (18). The variant E446 resides in a region of the
rotein reported to harbor mutations associated with atrial
Figure 2 SCN5A Sequencing Results of the Familial Cardiomyo
(A) Chromatograms demonstrating heterologous peaks in nucleotide sequence. Fo
sequenced, and 4 new missense mutations were identified among our dilated car
sense mutations of SCN5A superimposed on a schematic of the SCN5A protein (7
myopathy Registry, including the 4 new mutations reported here and D1275N idenbrillation (E428K, H445D, L461V, N470K, and R481W) u16). The E446 residue is conserved across species among the
ntire family of homologous voltage-gated sodium channels
ut not in the population of paralogous voltage-gated calcium
hannels (Online Table 2).
utation V1279I. The proband within the V1279I
c.3835.G¡A) pedigree presented later in life at the age of
0 years and had no symptoms of heart failure (NYHA
unctional class I) (Fig. 1, Table 1). He manifested signif-
cant arrhythmia including atrial fibrillation and nonsus-
ained ventricular tachycardia (Fig. 3A). He also showed a
enign outcome and remained stable for 4 years of follow-
p. Notably, in the family history exists a unique clinical
attern for the presence of conduction disease as indicated by
eft bundle branch block in the proband and a history of
acemakers in his mother and maternal grandmother.
This novel variant V1279I does not affect charge. The
hange occurs in the DIII-S3 transmembrane segment
Fig. 2) (18). The D1275N mutation identified in the
MD1E pedigree associated with conduction disorder,
ilation, and arrhythmia represents the only other reported
issense variant in this S3 transmembrane segment of this
rotein (7). Analogous S3 residue positions are almost
Registry
report, samples manifesting abnormal elution profile on the WAVE system were
pathy (DCM) population. (B) Relative locations of all currently reported DCM mis-
). Red denotes 5 total missense mutations identified within the Familial Cardio-
previously (7).pathy
r this
diomyo
,8,10
tifiedniversally conserved across domains II, III, and IV of the
Clinical Data for 5 Pedigrees Carrying SCN5A MutationsTable 1 Clinical Data for 5 Pedigrees Carrying SCN5A Mutations
Subject Pedigree ID* Sex
Age at
Onset,
yrs†
Age at
Diagnosis,
yrs†
NYHA
Functional
Class Symptoms Arrhythmia
Conduction
System Disease
LVEF,
%
LVEDD,
cm
Coronary
Angiogram Outcome Follow-Up‡
II-1 R222Q M 25 26 1 Palpitations NSR, PVC 1,000/h,
NSVT, PAC
No 34 66 NL Stable, LVEF 46% 172
II-2 R222Q M 17 19 1 Tachycardia AA, AF, PVC 1,400/h,
NSVT 100 runs/h
No 37 65 NL NYHA functional
class II, LVEF
35%, ICD
177
III-1 F1520L M 25 26 1 Asymptomatic NSR, PVC 100 runs/h,
NSVT, PAC
No 35 81 N/A ICD, transplant
(38 yrs)
138
II-1 E446K M 24 24 2 DOE, fatigue,
palpitations, CP
No No 22 68 N/A LVEF 40% 39
III-1 V1279I M 20 50 1 Asymptomatic PAF, NSVT LBBB 51 61 N/A Stable, PSVT,
LVEF 50%, ICD
52
II-6 D1275N M 15 68 2 DOE, syncope AF, AFL LAFB (FS 23%) N/A N/A Stable 636
III:4 D1275N M 23 51 1 Fatigue, syncope AF 3rd AVB 50 55 N/A PM, stable 336
III:10 D1275N M 22 41 1 Palpitations SSS, AF 3rd AVB 74 47 N/A PM, AV nodal
ablation
180
III:14 D1275N M 29 41 2 Fatigue,
palpitations
SSS, AF 2nd AVB (FS 20%) 48 N/A PM, stable 228
III:15 D1275N M 34 47 1 Palpitations SSS, SVT, AF 1st AVB 51 52 N/A PM, stable 156
III:17 D1275N F 24 45 2 Palpitations Bradycardia NL (FS 30%) N/A N/A Stable
IV:2 D1275N M 17 24 1 Syncope PVC, VT 1st AVB, RBBB 80 47 N/A PM, stable 84
IV:8 D1275N F 14 20 1 Syncope SSS, AS, AF, SVT RBBB 56 35 N/A PM, stable 72
IV:9 D1275N F 16 16 2 DOE, palpitations,
syncope
AF, AS N/A 50 N/A N/A PM, DOE 48
IV:10 D1275N F 13 18 1 Palpitations SSS N/A 58 44 N/A PM, stable 60
*Pedigree identifier (ID) identifies dilated cardiomyopathy (DCM) family by related SCN5A mutation and correlates to Figure 1, or in the case of D1275N, to the pedigree as previously reported (7). †Age in years. ‡Follow-up is months after diagnosis.
AA  atrial arrhythmias; AF atrial fibrillation; AFL atrial flutter; AS atrial standstill; AVB atrioventricular block; CP chest pain; DOE dyspnea on exertion; FS fractional shortening; LAFB left anterior fascicular block; LBBB left bundle branch block; LVEDD left
ventricular end-diastolic dimension; LVEF  left ventricular ejection fraction; N/A  not available; NL  normal (absence of symptoms); No  no arrhythmia present; NSR  normal sinus rhythm; NSVT  nonsustained ventricular tachycardia; PAC  premature atrial
contraction; PAF paroxysmal atrial fibrillation; PM pacemaker; PSVT paroxysmal supraventricular tachycardia; PVC premature ventricular contraction; RBBB right bundle branch block; SSS sick sinus syndrome; SVT supraventricular tachycardia; VT ventricular
tachycardia.
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species (Online Table 3).
Single nucleotide polymorphisms. In addition to the novel
missense variants reported above, a number of unreported
single nucleotide polymorphisms (SNPs) were identified
through sequencing analysis (Table 2). The intronic SNPs
found in exons 10, 16, and 17 are adjacent to conserved
splicing consensus sequence. Analysis of the relevant 3= un-
translated region sequence utilizing NNSPLICE 0.9 (23)
showed no apparent or potentially disruptive splicing consen-
sus sequence changes at these positions. All of the exonic SNPs
listed represent synonymous changes.
Discussion
This screening of a large cohort of DCM families demon-
Figure 3 Early Arrhythmia in SCN5A Mutation Carriers
(A) Electrocardiogram of proband V1279I at the age of 47 years, showing atrial fib
found at a young age and followed for many years before the development of dilat
ing atrial fibrillation when the patient had a normal left ventricular ejection fractionstrates that SCN5A mutations may account for a modestproportion of DCM (1.7%) and provides further evidence
that altered electrical excitability of the SCN5A protein can
manifest as a dilation phenotype. Still, the specific mecha-
nism producing this phenotype remains unknown. The
cardiac sodium channel is responsible for the fast depolar-
ization of the myocardium and is critical for the mainte-
nance of impulse conduction in the heart (24). We note that
the heterozygous (/) SCN5A knockout mice show a
pattern of disease similar to that found among these DCM
families including conduction dysfunction and age-
dependent myocardial tissue changes with fibrosis (25).
The SCN5A DCM phenotype. In the majority of cases
we describe, conduction disturbances appear to be unrelated
to the degree of left ventricular dysfunction (Table 1). In
patient V1279I, left bundle branch block was the initial
n and left bundle branch block. The left bundle branch block was accidentally
diomyopathy. (B) Electrocardiogram of individual III-10 of family D1275N, show-
(see Table 1).rillatio
ed car
(74%)finding, presenting at young age and preceding, by many
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SCN5A Mutations in Dilated Cardiomyopathy May 24, 2011:2160–8years, the diagnosis of DCM at the age of 46 years (Table 1
and Fig. 3A, showing left bundle branch block and atrial
fibrillation at the age of 47 years). All but 1 index patient
among these pedigrees had a DCM phenotype; in family
D1275N, the index patient (IV-2) presented with an
arrhythmic phenotype, and was evaluated because of his
family history of DCM (7,8,26).
In family D1275N, as previously reported (7), conduction
disease as well as arrhythmias were the presenting symptoms
in 12 of 15 carriers (75%) and preceded the gradual
development of left ventricular dysfunction (Fig. 3B) (7). In
this family, the DCM phenotype predominantly manifested
with age-related penetrance. As shown in Table 1, a dilated
and dysfunctioning myocardium was present in the older
generations, whereas at younger age, the arrhythmic trait
predominated. Four family members (III-15, III-17, IV-8,
and IV-10) (Table 1) had isolated arrhythmia and were
identified though family screening. For these persons, mean
age at diagnosis was 27 years. For comparison, the 5
D1275N mutation carriers with either dilation and/or LV
dysfunction had a mean age of 41 years (7).
Strikingly, each of the 5 missense mutations we identified
exhibit absolute conservation when compared to analogous
positions within the cardiac sodium ion channels of varied
species. For mutations D1275N, F1520L, V1279I, and
R222Q, conserved identity extends across the entire family
of voltage-gated sodium ion channels (Online Tables 1, 2,
and 3). In addition, position V1279 is identically conserved
across domains II, III, and IV of both voltage-gated sodium
and voltage-gated calcium channels (Online Table 3). Con-
servation at position R222 is absolute across every alignment
attempted, including all domains of related voltage-gated
sodium, calcium, and potassium channels, and even the
more distantly related transient receptor protein channels
Online Table 1).
With well over 160 disease-associated mutations reported
or this protein, the screening of SCN5A has undoubtedly been
thorough (24). A comprehensive review of the published
Novel SCN5A Single NucleotideP lymorphisms Identified in FamilialCardiomyopathy Registry Scre n ng*
Table 2
Novel SCN5A Single Nucleotide
Polymorphisms Identified in Familial
Cardiomyopathy Registry Screening*
Intronic Exonic
Exon 3 24CT
Exon 4 16GC, 60AT
Exon 6 45CA V210V GTGGTA
Exon 9 34GA P336P CCGCCA
Exon 10 3CA
Exon 12 15TC P627P CCGCCA
Exon 15 12 GA L771L CTCCTT
Exon 16 5CA, 13CT
Exon 17 6CA
Exon 24 38TA, 43Ins
*The SCN5A screening identified a number of unreported nucleotide changes among our dilated
cardiomyopathy population. Within coding regions, these changes are all consensus alterations or
silent substitutions and are not believed to be associated with disease manifestation.literature showed no previous reports identifying novel muta- ttions E446K, V1279I, or 1520L. In the case of position
V1279, we evaluated an additional 300 ethnically matched
chromosomes as position V1279 falls in the same exon for
which controls were investigated for the adjacent D1275
position (7). The screening of 506 chromosomal controls for
R222Q has also already been reported (10). Furthermore, we
screened 550 chromosomes from the Familial Cardiomyop-
thy Registry for this report, and each of our mutations
ppeared only once. These data support the observation that
hese mutations are not merely rare polymorphisms.
SCN5A is a member of a family of voltage-gated sodium
on channels that express primarily in neurons and muscle
bers, and SCN5A expresses almost exclusively in the heart
uscle (18). This channel initiates the upstroke of the
ction potential in myocyte depolarization, depolarizing
embrane potentials by allowing a rapid influx of sodium
ons. The resulting depolarizing current serves to signal
ownstream sarcomeric contraction within the myocyte.
hese depolarizations play a predominate role in the timing
nd initiation of global myocardium contraction by signal-
ng through gap junctions to adjacent myocytes and along
he specialized conduction pathways of the heart (27).
Heterozygous mutations in SCN5A have been shown to
ause cardiomyopathies that are characterized by a strong
onduction-related component. Functional studies of these
utations demonstrated both gain of function and loss of
unction variants that disrupt the natural rhythms of polariza-
ion and depolarization in the cardiac cycle. Gain of function
utations in the long-QT syndrome caused prolonged sodium
urrent during depolarization due to deficits in the fast-
nactivation or inactivation-gated states leading to the observed
rrhythmias (28–30). Mutant variants in Brugada syndrome
hifted the voltage dependence of steady-state inactivation in
he direction of more positive potentials, leading to an accel-
ration in recovery time from inactivation (31). In this form of
rugada syndrome, the resulting heterogeneity of the refrac-
ory period between the wild-type and mutant forms of the
odium channel has been suggested to result in an ideal
lectrical substrate for re-entrant arrhythmia (32). The SCN5A
utations associated with atrioventricular conduction block
ere shown to impair fast inactivation without producing
on-inactivating currents (33). A reduction of sodium current
ensity and an enhancement of slower inactivation compo-
ents resulted in a significant reduction in myocardial conduc-
ion velocity, leading to the observed blocks (33).
Analysis of the clinical features of the mutation carriers in
ll 5 pedigrees we identified indicates a tendency for earlier
ge of onset (ranging from 15 to 34 years in all but 1
atient). Furthermore, carriers exhibit a predominant ar-
hythmic phenotype (93% of cases in this study) with
upraventricular arrhythmias (86%) including sinus node
ysfunction (33%), atrial fibrillation (60%), ventricular
achycardia (33%), and conduction defects (60%) (Table 1).
hese data complement the observations of Olson et al. (8),
ho reported finding 3 additional SCN5A mutations and aruncation in their patient population; in each instance
t
I
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May 24, 2011:2160–8 SCN5A Mutations in Dilated Cardiomyopathycited, the SCN5A variation was associated with atrial fibril-
lation, impaired automaticity, and conduction delay. In the
majority of our cases, carriers were asymptomatic or mini-
mally symptomatic for heart failure and had a benign
outcome over an extended period of follow-up (39 to 172
months) (Table 1). Only family F1520L appeared to have a
more severe and progressive myocardial disease, with 2
patients undergoing transplantation (Fig. 1), indicating a
variable expressivity of the phenotype. A limited number of
patients were at risk of life-threatening events requiring
primary prevention with implantable cardioverter-defibrillators
(Table 1), and this was essentially related to the more severe
degree of left ventricular dysfunction. No patients exhibited
either long-QT syndrome or Brugada syndrome; specifi-
cally, no QT prolongation or shortening, T-wave abnor-
malities similar to those seen in long-QT syndrome, or
“Brugada sign” were observed in our patients. Together,
these findings support the hypothesis that the clinical
features of DCM-related SCN5A channelopathies substan-
ially and uniquely overlap (24).
nsights into the functional role of SCN5A mutations in
DCM. This report brings the total number of DCM-related
SCN5A missense mutations to 9: T220I, R222Q, E446K,
R814W, D1275N, V1279I, D1595H, F1520L, and I1835T
(Fig. 2) (7,8,10). Of those 9, 6 localize to the S3 or S4
transmembrane segments (T220I, R222Q, and R814W, S4
regions in protein reference #Q14524 [Online Table 1]; and
D1275N, V1279I, and D1595H, S3 regions in protein refer-
ence #Q14524 [Online Table 3]). Interestingly, recent crystal-
lographic data on the related voltage-gated potassium channel
Kv1.1 provides an estimate of the spatial relationship of the S3
and S4 regions. The crystallographic data were not able to
resolve the S3 subunit and related linker loops. Instead, an
alanine helix of appropriate length was inserted, and the S3
orientation was estimated based on its fit within the monomer
and tetramer structures and within the physical length restric-
tions of interlinking amino acid loops (34,35). Although this
model supports the functional hypothesis of an S3 to S4
charge-stabilizing interface, it does not provide enough infor-
mation for actual physical characterization or molecular mod-
eling of this relationship.
Variant T220I in domain I, transmembrane segment S4, of
SCN5A has not been investigated electrophysiologically. In
mutations R222Q and R814W, alterations occur in adjacent
conserved arginine residues within S4 (domain I, S4, and
domain II, S4, of SCN5A, respectively) (Fig. 2, Online
Table 1) that contribute positive charge essential for voltage
sensing across the cell membrane. These specific arginine
residues within S4 have been investigated in the homolo-
gous voltage-gated potassium channel Shaker, and alter the
gating function without modifying permeation (20,36–38).
Analysis of R814W in SCN5A expressed in heterologous
mammalian cell lines shows that this variant activates at a
more negative membrane potential and opens with slower
kinetics than the wild-type channel (39).Variant V1279I in domain III, transmembrane segment
S3, of SCN5A has not been investigated electrophysiologi-
cally. Two mutations also in S3 have been electrophysi-
ologically analyzed; mutations D1275N and D1595H occur
in analogous conserved aspartate residues within domain 3,
S3, and domain 4, S3, respectively, of SCN5A (Fig. 2,
Online Table 3). Alterations at this position in voltage-
gated potassium channels affect gating without modifying
permeation properties, mimicking affects similar to those
mentioned in alterations of the conserved arginine residues
of S4 (38,40). The D1595H SCN5A variant expressed in
heterologous mammalian cell lines activates normally, but
the kinetics of current decay are slower than wild-type
channels (39). The D1275N SCN5A variant expressed in
Xenopus oocytes results in a small decrease in recovery times
from fast inactivation, with a depolarizing shift of 3.8 mV in
voltage dependence of activation when compared to the
wild-type channels (41).
Given the high rate at which DCM-associated mutations
occur in S3 and S4 transmembrane regions of highly conserved
homologous domains, and among charge clusters believed to
interact directly in voltage-dependent gating, these data sug-
gest that some instances of DCM are intrinsically tied to the
disruption of voltage-sensing kinetics in SCN5A function.
Study limitations. A study limitation is represented by the
lack of segregation data in 3 of our families, because relatives
were not available for genetic investigations. This limitation,
common to human genetic studies and clinical genetic testing,
is compensated by other consensus criteria, as described in the
Methods section (42). Furthermore, more expression data to
explore the mechanistic link of the new SCN5Amutations with
DCM in mice models warrant future research.
Conclusions
Mutations in SCN5A in conjunction with DCM occur at a
frequency of 1.7% within our study population and, as
previously reported, may affect both familial and sporadic
cases. The majority of DCM-related SCN5A mutations
localize to highly conserved homologous S3 and S4 trans-
membrane segments, supporting the hypothesis for disrup-
tion of the sodium-channel voltage sensor in the etiology of
dilation remodeling. Not surprisingly, SCN5A mutation
carriers show a pattern of severe arrhythmia including atrial
fibrillation and ventricular tachycardia, and a better under-
standing of the molecular basis of these symptoms will have
important implications for the diagnosis and clinical man-
agement of DCM in these persons.
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